Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod with Radiation and Temozolomide in High Grade Glioma
NCT02490930Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fingolimod in lymphopenia, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Incidence of greater than or equal to Grade III infections attributable to fingolimod-induced lymphopenia at 4 months. Started Jul 2015; status: completed.
02
Drugs
fingolimod
03
Conditions
lymphopenia
Beyond the preview
Go deeper on NCT02490930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02490930.